In this roundtable discussion published in Corporate Disputes, Sean Sheridan and two other panelists discuss recent trends in patent disputes. Dr. Sheridan dicusses the sharp decline in petitions for inter partes review filed at the Patent Trial and Appeal Board (PTAB) as well an an increase in the number of bills seeking to limit patent protection for pharmaceutical and biologic products.
Click the link below to download a PDF of the article.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...